Novo launches introductory self-pay offer for Wegovy, Ozempic for $199 per month

Novo Nordisk (NVO) announced that Wegovy injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited time price of $199 per month to new self-pay patients between now and March 31, 2026. “This introductory offer is good for the first two months of therapy and applies to the two lowest doses (0.25 mg and 0.5 mg) of Wegovy or Ozempic. After those two months, patients will move to the new standard monthly self-pay price which Novo Nordisk is lowering from $499 to $349 per month*, also beginning today. These offers follow the recent agreement with the US Administration to expand access to medicines for patients living with obesity and other chronic conditions like diabetes, while lowering prices in the direct-to-patient, self-pay channel in 2026 – and today, Novo Nordisk is bringing these prices to consumers months in advance of that commitment,” the company stated. Novo Nordisk’s new cash-pay offers are available through Wegovy.com or Ozempic.com, the company’s direct-to-consumer pharmacy, NovoCare, and other participating organizations and telehealth providers that work directly with the drugmaker, including Costco (COST), GoodRx (GDRX), WeightWatchers (WW), Ro, LifeMD (LFMD) and eMed, the company noted.